TICKERNERD
Menu
ZNTLZNTLHealthcare · Biotechnology

ZNTL Stock Forecast: Zentalis Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$4.65
−1.90% on the day

The 10 Wall Street analysts covering Zentalis Pharmaceuticals, Inc. hold a median 12-month price target of $6 — +29.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$337.4M
Ticker Nerd rank
75 / 100
Median analyst target
$6.00
Analysts covering
10
Total return, dividends reinvested
1W
+3.1%
1M
+4.3%
YTD
+244.4%
1Y
+247.0%
From 52W high
−29.7%
From 52W low
+263.3%
$1.28
$6.61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZNTL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zentalis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Growth
80
Quality
64
Accruals
62
Value
61
Size
59
Issuance
59
Revisions
42
Volatility
14

Momentum (94): The shares have been drifting up relative to others.

Volatility (14): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Zentalis Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

ZNTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZNTL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26ZNTLHigh $10.00Median $6.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
5 Buy5 Hold0 Sell
Low $4.00Median $6.00High $10.00

The green dot is the last close — the median target sits +29.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 July 2026Rodman & RenshawInitiatesBuy$11
17 July 2026MizuhoInitiatesOutperform$8.00
10 Apr 2026GuggenheimMaintainsBuy—
27 Mar 2026GuggenheimReiteratesBuy—
12 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Aug 2025Wells FargoMaintainsEqual-Weight—
15 May 2025HC Wainwright & Co.ReiteratesBuy—
15 May 2025WedbushReiteratesNeutral—
28 Mar 2025WedbushReiteratesNeutral—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025Wells FargoMaintainsEqual-Weight—
29 Jan 2025HC Wainwright & Co.MaintainsBuy—
28 Jan 2025UBSMaintainsNeutral—
15 Nov 2024GuggenheimMaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024OppenheimerReiteratesOutperform—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024WedbushUpgradeNeutral—
20 June 2024UBSDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ZNTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Zentalis Pharmaceuticals, Inc. (ZNTL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.5×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
1.8×

Cheaper than 48% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−51.9%

Higher than 21% of US stocks

Return on assets
−27.9%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ZNTL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZNTLZentalis Pharmaceuticals, Inc.$337.4M
75
RCKTRocket Pharmaceuticals, Inc.$336.6M
64
AGENAgenus, Inc.$335.6M
89
UPBUpstream Bio, Inc.$340.2M
29
DMACDiaMedica Therapeutics, Inc.$341.6M
35
CMPXCompass Therapeutics, Inc.$327.7M
29
LXEOLexeo Therapeutics, Inc.$324.3M
35
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZNTL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ZNTL news & analysis

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Aug 2026neutral

On August 3, 2026, the Compensation Committee of Zentalis Pharmaceuticals' Board of Directors granted non-qualified stock options for an aggregate of 84,000 shares of common stock to two newly hired employees. The options were issued under the company's 2022 Employment Inducement Incentive Award Plan as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — A ZNTL watcher would care because this discloses recent hiring and equity-based compensation incentives, which are standard inducement grants tied to bringing new employees on board.

FAQ

Frequently asked questions about ZNTL stock

What is the ZNTL stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Zentalis Pharmaceuticals, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZNTL stock a buy right now?

Of the 10 analysts covering Zentalis Pharmaceuticals, Inc., 5 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zentalis Pharmaceuticals, Inc. 75 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZNTL?

As at 1 Aug 2026, Zentalis Pharmaceuticals, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will ZNTL stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +29.0% from the last close, and Ticker Nerd's factor model ranks Zentalis Pharmaceuticals, Inc. 75 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZNTL stock forecast for 2030?

No analyst covering Zentalis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZNTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has ZNTL stock performed over the past year?

Zentalis Pharmaceuticals, Inc. returned +247.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zentalis Pharmaceuticals, Inc. do?

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways of cancer.

What is the latest news on ZNTL?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". On August 3, 2026, the Compensation Committee of Zentalis Pharmaceuticals' Board of Directors granted non-qualified stock options for an aggregate of 84,000 shares of common stock to two newly hired employees. The options were issued under the company's 2022 Employment Inducement Incentive Award Plan as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways of cancer. It maintains a broad pipeline of product candidates, with an initial emphasis on validated oncology targets designed to address large patient populations. The company advances innovative therapies, including a first-in-class WEE1 inhibitor in late-stage development and biomarker-driven treatments for ovarian cancer. Zentalis Pharmaceuticals, Inc. operates within the health technology and biotechnology sectors, contributing to oncology research by pursuing small molecule approaches to improve cancer treatment options. Founded in 2014 and headquartered in San Diego, California, it dedicates efforts to groundbreaking research in clinical-stage oncology programs.

CEO Ms. Julie M. Eastland M.B.A. · 106 employees · United States · https://zentalis.com